U-Factor Holdings Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; Representative Director: Hidehiro Ijima; hereinafter "the Company") has decided to adopt "WAVEBASE," a data analysis system provided by Toyota Motor Corporation (Headquarters: Toyota City, Aichi Prefecture; President: Koji Sato; hereinafter "Toyota"). The Company will leverage all kinds of cross-sectional data, such as protein data from stem cell supernatant, to innovate its analysis system for drug discovery research. Preparations for implementation, including requirements definition and environment design, have begun, targeting introduction in April 2026.

1. Key Points of This Release

・Decision to adopt "WAVEBASE" to strengthen the analysis platform for stem cell supernatant drug discovery research ・Establishment of an integrated analysis system for stem cell supernatant protein data and other relevant data ・Scheduled to begin implementation around April 2026

2. Background

Drug discovery research for stem cell supernatant requires handling diverse data across various domains. The Company has been considering strengthening its analysis platform, with the handling of research data and the establishment of analysis processes as important issues.

3. This Initiative (Roles of Each Company)

The Company: Design of data integration and analysis operations in drug discovery research, utilization in R&D Toyota: Provision of the data analysis system "WAVEBASE," technical support

4. Future Plans

Scheduled implementation: April 2026 *The conclusion of the contract and the implementation period may change depending on future discussions and procedures.

5. About "WAVEBASE"

"WAVEBASE" is a cloud-based data analysis service provided by Toyota. The decision to adopt it was made with the aim of supporting analysis operations for diverse data in the Company's research and development. WAVEBASE | TOYOTA

6. What is Our Unique Stem Cell Supernatant "U-Factor® Liquid"?

The Company has refined the supernatant obtained during the process of culturing stem cells using its proprietary technology and named the highly pure stem cell supernatant U-Factor® Liquid (Registration No.: 6396893). It contains a large amount of cytokines (proteins with physiological activity) secreted by stem cells. We believe that U-Factor® Liquid, refined through repeated improvements and special methods, has very significant potential regarding safety and efficacy.

7. Company Overview

U-Factor Holdings Co., Ltd. Location: 6-4-6 Kojimachi, Chiyoda-ku, Tokyo 102-0083 Representative: Hidehiro Ijima, Representative Director Established: February 4, 2026 Business Activities: Group-wide management strategy formulation and management https://u-factor.com

Toyota Motor Corporation Location: 1 Toyota-cho, Toyota City, Aichi Prefecture 471-8571 Representative: Koji Sato, President Established: August 28, 1937 Business Activities: Automobile production and sales https://global.toyota/jp/

[Contact for this release] U-Factor Holdings Co., Ltd. Public Relations TEL: 03-5357-1580 Email: info@u-factor.com

FACT BOX

  • Source: PR TIMES
  • Category: News